MiCardia, a developer of cardiac devices, has received CE mark approval for its enCorSQ Mitral Valve Repair System.
The enCorSQ is an intra-operative device which is implanted surgically to treat mitral regurgitation (MR) and enables the physician to adjust the device without another surgery to correct any recurrent mitral valve regurgitation.
The device also allows the surgeon to address any residual MR or coaptation correction, real-time, off-pump, on a beating heart.
MiCardia CEO Don Rohrbaugh said the Mitral Valve Repair System has the capability to be adjusted with the company’s proprietary enCor MC-100 RF generator to increase coaptation of the leaflets and address recurrent mitral regurgitation.
MiCardia CMO Maurice Buchbinder said the enCorSQ device from MiCardia is a true paradigm shift in surgical repair of mitral regurgitation using annuloplasty rings.